About Ankylosing Spondylitis
Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.
TechNavio's analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:
• TNF Inhibitors
• COX Inhibitors
• Others
On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below:
• Biologics
• Small Molecules
On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows:
• Oral
• Parenteral
In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease:
• Solid
• Liquid
The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Also, the late-stage pipeline molecules developed for the treatment of Ankylosing Spondylitis have been discussed.
TechNavio's report, Global Ankylosing Spondylitis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA; it also covers the Global Ankylosing Spondylitis market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Abbvie
• Amgen
• Janssen Pharmaceuticals
• Merck & Co.
• Pfizer
Other Prominent Vendors
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Celltrion
• Eisai
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Otsuka Pharmaceutical
• Regeneron Pharmaceuticals
• Sanofi
• Shanghai Pharmaceuticals
• UCB
Market Driver
• Presence of Unmet Need
• For a full, detailed list, view our report
Market Challenge
• Threat from Patent Expiry
• For a full, detailed list, view our report
Market Trend
• Market Dominance by Biologics
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Causes of Ankylosing Spondylitis
06.3 Pathophysiology
06.4 Epidemiology
06.5 Diagnosis
06.6 Treatment and Management
06.6.1 Analgesics
06.6.2 Corticosteroids
06.6.3 DMARDs
06.6.4 Biologics
06.6.5 Physiotherapy
06.6.6 Surgery
06.7 Economic Burden
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Mechanism of Action
08.1 TNF Inhibitors
08.2 COX Inhibitors
08.3 Others
09. Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Small Molecules
10. Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11. Market Segmentation by Dosage Forms
11.1 Solid
11.2 Liquid
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of the Top Drugs for Ankylosing Spondylitis
20.2.2 Abbvie
20.2.3 Janssen Pharmaceuticals
20.2.4 Amgen
20.2.5 Pfizer
20.2.6 Merck
20.3 Other and Future Prominent Vendors
21. Pipeline Portfolio
22. Key Vendor Analysis
22.1 AbbVie Inc.
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Product Segmentation by Revenue 2013
22.1.4 Product Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Developments
22.1.8 SWOT Analysis
22.2 Amgen
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2013
22.2.4 Product Portfolio by Revenue 2013
22.2.5 Business Segmentation by Revenue 2012 and 2013
22.2.6 Geographical Segmentation by Revenue 2013
22.2.7 Business Strategy
22.2.8 Recent Developments
22.2.9 SWOT Analysis
22.3 Janssen Pharmaceuticals
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Recent Developments
22.3.4 SWOT Analysis
22.4 Merck
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.5 Pfizer
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue
22.5.6 Business Strategy
22.5.7 Key Developments
22.5.8 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Executive Summary of Global Ankylosing Spondylitis Market 2014-2019
Exhibit 3: Snapshot of Ankylosing Spondylitis
Exhibit 4: Diagnosis of Ankylosing Spondylitis
Exhibit 5: Treatment and Management of Ankylosing Spondylitis
Exhibit 6: Snapshot of the Economic Burden of Ankylosing Spondylitis
Exhibit 7: Snapshot of the Global Ankylosing Spondylitis Market
Exhibit 8: Global Ankylosing Spondylitis Market 2014-2019 (US$ million)
Exhibit 9: Drivers and Challenges of Global Ankylosing Spondylitis Market
Exhibit 10: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action
Exhibit 11: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action 2014
Exhibit 12: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule
Exhibit 13: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule 2014
Exhibit 14: Global Ankylosing Spondylitis Market Segmentation by Route of Administration
Exhibit 15: Global Ankylosing Spondylitis Market Segmentation by Route of Administration 2014
Exhibit 16: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms
Exhibit 17: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms 2014
Exhibit 18: Global Ankylosing Spondylitis Market by Geographical Segmentation 2014
Exhibit 19: Buying Criteria of the Global Ankylosing Spondylitis Market
Exhibit 20: Drivers and their Impact on the Key Customer Category of the Global Ankylosing Spondylitis Market
Exhibit 21: Drivers and Their Geography-wise Impact on the Global Ankylosing Spondylitis Market
Exhibit 22: YoY Sales Comparison of Top Drugs used for Ankylosing Spondylitis 2010-2013 (US$ million)
Exhibit 23: Revenue Share of the Top Drugs used for Ankylosing Spondylitis 2010-2013
Exhibit 24: Abbvie: Product Portfolio for Ankylosing Spondylitis
Exhibit 25: YoY Global Sales of Humira 2008-2013 (US$ million)
Exhibit 26: Janssen: Product Portfolio for Ankylosing Spondylitis
Exhibit 27: YoY Sales of Remicade 2005-2013 (US$ million)
Exhibit 28: YoY Sales of Simponi 2010-2013 (US$ million)
Exhibit 29: Amgen: Product Portfolio for Ankylosing Spondylitis
Exhibit 30: YoY Sales of Enbrel (In US and Canada) 2005-2013 (US$ million)
Exhibit 31: YoY Sales of Enbrel In US 2005-2013 (US$ million)
Exhibit 32: YoY Sales of Enbrel In Canada 2005-2013 (US$ million)
Exhibit 33: Region-wise Sales Comparison of Enbrel 2005-2013 (US$ million)
Exhibit 34: Pfizer: Product Portfolio for Ankylosing Spondylitis
Exhibit 35: YoY Sales of Enbrel (Outside US and Canada) 2009-2013 (US$ million)
Exhibit 36: YoY Sales of Enbrel (Outside US and Canada) 2008-2013 (US$ million)
Exhibit 37: Merck: Product Portfolio for Ankylosing Spondylitis
Exhibit 38: YoY Sales of Remicade 2005-2013 (US$ million)
Exhibit 39: YoY Sales of Simponi 2010-2013 (US$ million)
Exhibit 40: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 41: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 42: AbbVie Inc.: Sales by Geography 2013
Exhibit 43: Amgen: Business Segmentation by Revenue 2013
Exhibit 44: Amgen: Product Portfolio by Revenue 2013
Exhibit 45: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 46: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 47: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 48: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 49: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 50: Pfizer: Business Segmentation by Revenue 2013
Exhibit 51: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 52: Pfizer: Geographical Segmentation by Revenue 2013
